Endpoints in stem cell trials in ischemic heart failure

Stem Cell Research and Therapy

Volumn 6, Issue 1, 2015, Pages

  Banovic, Marko ^a   Loncar, Zlatibor ^a   Behfar, Atta ^b   Vanderheyden, Marc ^c   Beleslin, Branko ^a   Zeiher, Andreas ^d   Metra, Marco ^e   Terzic, Andre ^b   Bartunek, Jozef ^c  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b MAYO CLINIC   (United States)

^c OLV HOSPITAL   (Belgium)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOCARDIOGRAPHY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELLS BY BODY ANATOMY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); EVIDENCE BASED MEDICINE; FLUOROSCOPY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; ISCHEMIC HEART FAILURE; NONHUMAN; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REGENERATIVE MEDICINE; REVIEW; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; ADVERSE EFFECTS; BIOASSAY; MYOCARDIAL ISCHEMIA; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS; STATISTICS AND NUMERICAL DATA;

ENDPOINT DETERMINATION; HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEM CELL TRANSPLANTATION;

EID: 84940381314     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/s13287-015-0143-9     Document Type: Review

References (44)

1. Hanna BE, Hennebry TA, Abu-Fadel MS. Combined reperfusion strategies in ST-segment elevation MI: rationale and current role. Clev Clin J Med. 2010;77:629-38.
2. Kovacic JC, Castellano JM, Fuster V. Cardiovascular defence challenges at the basic, clinical, and populations level. Ann N Y Acad Sci. 2012;1254:1-6.
3. Bartunek J, Vanderheyden M, Hill J, Terzic A. Cells as biologic for cardiac repair in ischemic heart failure. Heart. 2010;96:792-800.
4. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J. 2008;29:1807-18.
5. Abdel-Latif A, Bolli R, Tieyjeh IM, Montori VM, Perin EC, Hornung CA, et al. Adult bone marrow- derived cells for cardiac repair: a systematic review and meta analysis. Arch Intern Med. 2007;167:989-97.
6. Stanley K. Design of randomized controlled trials. Circulation. 2007;115:1164-9.
7. Hare JM, Bolli R, Cooke JP, Gordon DJ, Henry TD, Perin EC, et al. Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the cardiovascular cell therapy research network (CCTRN). Circulation. 2013;127:1630-5.
8. Behfar A, Crespo-Diaz R, Nelson TJ, Terzic A, Gersh BJ. Stem cells: clinical trials results the end of the beginning or the beginning of the end? Cardiovasc Hematol Disord Drug Targets. 2010;10:186-201.
9. Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. Nature. 2008;453:322-9.
10. Hansson EM, Lindsay ME, Chien KR. Regeneration next: toward heart stem cell therapeutics. Cell Stem Cell. 2009;5:364-77.
11. Behfar A, Crespo-Diaz R, Terzic A, Gersh BJ. Cell therapy for cardiac repair - lessons from clinical trials. Nat Rev Cardiol. 2014;11:232-46.
12. Duckers HJ, Houtgraaf J, Hehrlein C, Schofer J, Waltenberger J, Gershlick A, et al. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. Eurointervention. 2011;7:805-12.
13. Bartunek J, Sherman W, Vanderheyden M, Fernandez-Aviles F, Wijns W, Terzic A. Delivery of biologics in cardiovascular regenerative medicine. Clin Pharmacol Ther. 2009;85:548-52.
14. Furlani D, Ugurlucan M, Ong L, Bieback K, Pittermann E, Westien I, et al. Is the intravascular administration of stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc Res. 2009;77:370-6.
15. Kandala J, Upadhyay GA, Pokushalov E, Wu S, Drachman DE, Singh JP. Meta-analysis of stem-cell therapy in chronic ischemic cardiomyopathy. Am J Cardiol. 2013;112:217-25.
16. Behfar A, Latere JP, Bartunek J, Homsy C, Daro D, Crespo-Diaz RJ, et al. Optimized delivery system achieves enhanced endomyocardial stem cell retention. Circ Cardiovasc Interv. 2013;6:710-8.
17. Prowse ABJ, Timmins NE, Yau TM, Li RK, Weisel RD, Keller G, et al. Transforming the promise of pluripotent stem cell-derived cardiomyocites to a therapy: challenges and solutions for clinical trials. Can J Cardiol. 2014;30:1335-49.
18. Wu J, Zeng F, Huang XP, Chung JC, Konecny F, Weisel RD, et al. Infarct stabilization and cardiac repair with a VEGF-conjugated, injectable hydrogel. Biomaterials. 2011;32:579-86.
19. Dib N, Khawaja H, Warner S, McCarthy M, Campbell A. Cell therapy for cardiovascular disease: a comparison of methods of methods of delivery. J Cardiovasc Transl Res. 2011;4:177-81.
20. Van Laake LW, Passier R, Monshouwer-Kloots J, Verkleij AJ, Lips DJ, Freund C, et al. Human embryonic stem cells-derived cardiomyocites survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Res. 2007;1:9-24.
21. Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61:2329-38.
22. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369-79.
23. Zhang H, Song P, Tang Y, Zhang X-I, Zhao S, Wei Y, et al. Injection of bone marrow mesenchymal stem cells in the borderline area of infracted myocardium: heart status and cell distribution. J Thorac Cardiovasc Surg. 2007;134:1234-40.
24. Heldman AW, DiFede DL, Fishman JL, Zambrano JP, Trachtenberg BH, Karantalis V, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT Randomized Trial. JAMA. 2014;311:62-73.
25. George B. Regulations and guidelines governing stem cell based products: clinical considerations. Perspect Clin Res. 2011;2:94-9.
26. US Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for human somatic cell therapy and gene therapy. 1998. [ http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm072987.htm ].
27. Bartunek J, Dimmeler S, Drexler H, Fernandez-Aviles F, Galinanes M, Janssens S, et al. The consensus of the task force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for repair of the heart. Eur Heart J. 2006;27:1338-40.
28. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2010;56:392-406.
29. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44-51.
30. Wittes J, Lakatos E, Probstfield J. Surrogate endpoints in clinical trials: cardiovascular diseases. Stat Med. 1989;8:415-25.
31. Klein C. Magnetic resonance imaging and positron emission tomography as predictors of heart failure. Heart Metab. 2009;42:15-20.
32. Hopp E, Lunde K, Solheim S, Aakhus S, Arnesen H, Forfang K, et al. Regional myocardial function after intracoronary bone marrow cell injection in reperfused anterior wall infarction - a cardiovascular magnetic resonance tagging study. J Cardiovasc Magn Reson. 2011;13:22. doi: 10.1186/1532-429X-13-22.
33. Fuster V, Sanz J, Viles-Gonzalez JF, Rajagopalan S. The utility of magnetic resonance imaging in cardiac tissue regeneration trials. Nat Clin Practice Cardiovasc Med. 2006;3:S2-7.
34. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2000;2:271-8.
35. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, et al. Clinical end-points in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013;15:1082-94.
36. Dargie H. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-90.
37. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999;18:1341-54.
38. Costa V, McGregor M, Laneuville P, Brophy JM. The cost-effectiveness of stem cell transplantations from unrelated donors in adult patients with acute leukemia. Value Health. 2007;10:247-55.
39. Kang H-J, Kim H-S, Zhang S-Y, Park K-W, Cho H-J, Koo B-K, et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet. 2004;363:751-6.
40. Dib N, Dinsmore J, Lababidi Z, White B, Moravec S, Campbell A, et al. One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study). JACC Cardiovasc Interv. 2009;1:9-16.
41. Assmus B, Fischer-Rasokat U, Honold J, Seeger FH, Fichtlscherer S, Tonn T, et al. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry. Circ Res. 2007;100:1234-41.
42. Perin E, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DXM, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic ischemic heart failure: the FOCUS-CCTRN trial. JAMA. 2012;307:1717-26.
43. Poglajen G, Sever M, Cukjati M, Cernelc P, Knezevic I, Zemljic G, et al. Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy. Circ Cardiovasc Interv. 2014;4:552-9.
44. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378:1847-57.